Insider Selling: AnaptysBio, Inc. (NASDAQ:ANAB) Insider Sells 8,720 Shares of Stock

AnaptysBio, Inc. (NASDAQ:ANAB) insider Eric J. Loumeau sold 8,720 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $39.82, for a total value of $347,230.40. Following the completion of the sale, the insider now owns 7,020 shares of the company’s stock, valued at approximately $279,536.40. The sale was disclosed in a filing with the SEC, which is accessible through this link.

AnaptysBio Price Performance

ANAB stock traded down $1.22 during mid-day trading on Tuesday, reaching $37.50. The company had a trading volume of 340,978 shares, compared to its average volume of 329,314. The firm has a 50 day moving average of $35.23 and a 200 day moving average of $27.63. The company has a market capitalization of $1.02 billion, a PE ratio of -6.11 and a beta of -0.29. AnaptysBio, Inc. has a 12 month low of $13.36 and a 12 month high of $41.31.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82). The firm had revenue of $10.97 million for the quarter, compared to the consensus estimate of $25.85 million. AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. Analysts anticipate that AnaptysBio, Inc. will post -6.84 EPS for the current year.

Institutional Investors Weigh In On AnaptysBio

Several large investors have recently modified their holdings of ANAB. Frazier Life Sciences Management L.P. boosted its stake in shares of AnaptysBio by 140.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock valued at $54,270,000 after purchasing an additional 1,265,891 shares in the last quarter. First Light Asset Management LLC raised its position in shares of AnaptysBio by 56.4% in the 4th quarter. First Light Asset Management LLC now owns 1,237,178 shares of the biotechnology company’s stock worth $26,500,000 after acquiring an additional 446,372 shares in the last quarter. StemPoint Capital LP lifted its stake in shares of AnaptysBio by 499.0% during the 1st quarter. StemPoint Capital LP now owns 269,548 shares of the biotechnology company’s stock worth $6,070,000 after purchasing an additional 224,548 shares during the last quarter. Octagon Capital Advisors LP bought a new stake in AnaptysBio during the fourth quarter valued at about $2,570,000. Finally, Assenagon Asset Management S.A. grew its stake in AnaptysBio by 38.2% in the second quarter. Assenagon Asset Management S.A. now owns 306,633 shares of the biotechnology company’s stock valued at $7,684,000 after purchasing an additional 84,795 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on ANAB shares. Truist Financial upped their price objective on AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research note on Thursday, August 15th. JPMorgan Chase & Co. lifted their price objective on shares of AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Finally, HC Wainwright restated a “buy” rating and set a $55.00 price objective on shares of AnaptysBio in a research report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, AnaptysBio has an average rating of “Moderate Buy” and a consensus target price of $50.30.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.